Benzinga | Dec 22, 2020 08:45AM EST

Wedbush Downgrades IGM Biosciences to Neutral, Raises Price Target to $77

Wedbush downgrades IGM Biosciences (NASDAQ:IGMS) from Outperform to Neutral and raises the price target from $73 to $77.